ACCESS
This work brings together 16 countries, mainly represented by national public health agencies, medical product authorities, ministries of health and research institutes. To support sustainability build synergies, we are continuously working in close collaboration with key European stakeholders, including HERA, EMA, ECDC, WHO Europe and European pharmaceutical industry associations.
Focus products
EU-JAMRAI 2 partner countries have identified clinically important antibiotics and veterinary vaccines with a national vulnerable supply.
New products
EU-JAMRAI 2 are aiming to assist DG HERA and other European bodies in their efforts for strengthening access to new technologies, like novel antibiotics and bacteriophages.
Registered antibiotics for tuberculosis
Here you can find helpful information for a better understanding of which products are marketed, where, and under which regulatory pathway.
Webinar and presentations
EU-JAMRAI 2 is continuously gathering and sharing experiences, evidence, and best practices on key topics related to access to AMR-related products. Explore our recorded webinars:
How does the Access work performed in EU-JAMRAI 2 support the implementation of the EU Council recommendation of AMR?
The access work of EU-JAMRAI 2 supports the following recommendations:
Take appropriate national measures aimed at ensuring that, by 2030, at least 65 % of the total consumption of antibiotics in humans belongs to the Access group of antibiotics as defined in the AWaRe classification of the WHO (16) (by improving availability of antibiotics in the MS belonging to the Access group).
Promote in a coordinated manner with national and multicountry initiatives, the development of and accessibility to antimicrobials and other medical countermeasures relevant to combat AMR in humans […] (29)
Continue to support Member States in identifying priority antimicrobial resistant pathogens at Union and Member State level, in mapping existing, upcoming and missing AMR medical countermeasures, and in defining target product profiles in alignment with national initiatives (29a)
Improve the continuity of supply of antimicrobials and other AMR medical countermeasures in the EU, notably, in liaison with Member States, by supporting and coordinating Member States’ initiatives on the manufacturing, procurement and stockpiling and by addressing hurdles at EU level (29c)
Improve demand forecast, assessing and addressing antibiotics supply chain vulnerabilities, and implement targeted antibiotics stockpiling actions as appropriate, to avoid shortages. (29d)
Contribute to the design and governance of a Union multi-country pull incentive scheme in order to improve innovation, the development of new antimicrobials and access to existing and new antimicrobials where Member States can participate on a voluntary basis […]. (30)
Incentivise the development and placing on the market of effective and evidence-based alternatives to the use of antimicrobials and of vaccines for animal health (33)
Enhance the cooperation on AMR between professionals working in human health, veterinary, environment and agronomy sectors and with stakeholders, in order to improve the One Health approach on AMR. (36)
Other policy documents of importance for the access work of EU-JAMRAI 2:
UNGA Political Declaration: A global commitment to combat antimicrobial resistance.
Individual countries’ National Action Plans.